Zealand Pharma: royalty revenue from Sanofi on the rise
(CercleFinance.com) - Danish biotech company Zealand Pharma said royalty revenue from Sanofi's Soliqua rose by 30% to 7 million Danish kronor in fourth-quarter.
Over the full year of 2017, the group's total royalty revenue rose by 59% to 38.8 million Danish kronor, the company said on Wednesday.
Zealand - which receives 10% of Soliqua's sales - is still trying to reduce its dependence on Sanofi's insulin combination by promoting its own medications for rare diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Over the full year of 2017, the group's total royalty revenue rose by 59% to 38.8 million Danish kronor, the company said on Wednesday.
Zealand - which receives 10% of Soliqua's sales - is still trying to reduce its dependence on Sanofi's insulin combination by promoting its own medications for rare diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.